JPRN-UMIN000014189已完成未知
Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer - Recover HER2
JFCR Breast Med Oncol0 个研究点目标入组 0 人开始时间: 2014年6月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) active synchuronous cancer 2) active infectious disease
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpressioPatients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breastMedDRA version: 14.1Level: LLTClassification code 10006174Term: Breast adenocarcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065348Term: Breast adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2008-000528-22-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
未知
1 期
Clinical Evaluation of Lapatinib Administered with Capecitabine in Japanese Patients with ErbB2 Overexpressing Advanced or Metastatic Breast CancerJPRN-jRCT2080220386GlaxoSmithKline K.K.50
进行中（未招募）
不适用
A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial RadiotherapyBrain metastases from ErbB2-positive breast cancerMedDRA version: 8.1Level: LLTClassification code 10006128Term: Brain metastasesEUCTR2006-005912-28-IEGlaxoSmithKline Research & Development Ltd.110
进行中（未招募）
1 期
A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial RadiotherapyEstudio fase II de lapatinib y topotecán (Hycantin) o lapatinib y capecitabina (Xeloda) en el tratamiento de metástasis cerebrales recurrentes en pacientes con cáncer de mama ErbB2 positivo tras radioterapia cranealMetástasis cerebrales en pacientes con cáncer de mama ErbB2-positivoMedDRA version: 8.1Level: LLTClassification code 10006128Term: Brain metastasesEUCTR2006-005912-28-ESGlaxoSmithKline S.A.
进行中（未招募）
不适用
A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial RadiotherapyBrain metastases from ErbB2-positive breast cancerMedDRA version: 8.1Level: LLTClassification code 10006128Term: Brain metastasesEUCTR2006-005912-28-GRGlaxoSmithKline Research & Development Ltd.110